JP2023536999A5 - - Google Patents
Info
- Publication number
- JP2023536999A5 JP2023536999A5 JP2023507966A JP2023507966A JP2023536999A5 JP 2023536999 A5 JP2023536999 A5 JP 2023536999A5 JP 2023507966 A JP2023507966 A JP 2023507966A JP 2023507966 A JP2023507966 A JP 2023507966A JP 2023536999 A5 JP2023536999 A5 JP 2023536999A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- pharmaceutical composition
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061384P | 2020-08-05 | 2020-08-05 | |
| US63/061,384 | 2020-08-05 | ||
| PCT/EP2021/071824 WO2022029209A1 (en) | 2020-08-05 | 2021-08-05 | Oligonucleotide treatment of hepatitis b patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536999A JP2023536999A (ja) | 2023-08-30 |
| JP2023536999A5 true JP2023536999A5 (cg-RX-API-DMAC7.html) | 2024-08-14 |
Family
ID=77595500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507966A Pending JP2023536999A (ja) | 2020-08-05 | 2021-08-05 | B型肝炎患者のオリゴヌクレオチド処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357773A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192955A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023536999A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230043877A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194120A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021322891A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190794A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300340A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001443A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202221122A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029209A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| AU2022384619A1 (en) * | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| AU2024313135A1 (en) * | 2023-06-23 | 2026-01-22 | Brii Biosciences, Inc. | Assessment and treatment of chronic hepatitis b |
| EP4735477A2 (en) * | 2023-06-27 | 2026-05-06 | HBVtech LLC | Methods for reducing hepatitis b virus surface antigen (hbsag) and drugs used in the methods thereof |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| AU2025205193A1 (en) * | 2024-07-08 | 2026-01-29 | Hangzhou Tianlong Pharmaceutical Co., Ltd. | Double-Stranded RNAi Agents For Targeting And Regulating HBV Gene Expression, And A Use Thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| PL3114128T3 (pl) * | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| HUE053704T2 (hu) | 2014-12-08 | 2021-07-28 | Hoffmann La Roche | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| CA3013683C (en) * | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2017211791A1 (en) * | 2016-06-07 | 2017-12-14 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a tlr7 agonist |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| IL307295A (en) | 2017-01-06 | 2023-11-01 | Hoffmann La Roche | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[5,4-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran -2-yl]propyl]acetate |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
-
2021
- 2021-08-05 JP JP2023507966A patent/JP2023536999A/ja active Pending
- 2021-08-05 EP EP21763245.4A patent/EP4192955A1/en active Pending
- 2021-08-05 MX MX2023001443A patent/MX2023001443A/es unknown
- 2021-08-05 CA CA3190794A patent/CA3190794A1/en active Pending
- 2021-08-05 AU AU2021322891A patent/AU2021322891A1/en active Pending
- 2021-08-05 TW TW110128948A patent/TW202221122A/zh unknown
- 2021-08-05 KR KR1020237004356A patent/KR20230043877A/ko active Pending
- 2021-08-05 IL IL300340A patent/IL300340A/en unknown
- 2021-08-05 CN CN202180056772.5A patent/CN116194120A/zh active Pending
- 2021-08-05 WO PCT/EP2021/071824 patent/WO2022029209A1/en not_active Ceased
-
2023
- 2023-02-03 US US18/164,151 patent/US20230357773A1/en active Pending